Buddleja (Buddleja davidii)

Buddleja davidii, commonly called butterfly bush, contains bioactive iridoid glycosides and flavonoids such as luteolin and apigenin that drive its anti-inflammatory and antioxidant effects. These compounds inhibit pro-inflammatory enzymes and scavenge free radicals, though supporting evidence remains limited to in vitro and preclinical studies.

Origin & History

Buddleja davidii (butterfly bush) is a deciduous shrub native to northwestern China, now naturalized worldwide, belonging to the Scrophulariaceae family. The bioactive compounds are sourced from flowers, stems, and leaves through freeze-drying, aqueous extraction, or methanol extraction methods to isolate phenolic-rich compounds including flavonoids, phenylethanoid glycosides, and carotenoids.

Historical & Cultural Context

Buddleja species have been used for centuries in traditional Asian and Mediterranean medicine systems to treat wounds, liver diseases, bronchial complaints, eye issues, ulcers, and as diuretics and analgesics. Historical ethnopharmacological records document B. officinalis use for ophthalmic conditions and B. globosa for wound healing, though B. davidii specific traditional use is less documented.

Health Benefits

• Anti-inflammatory activity demonstrated in vitro with flower extracts (IC50: 28.6-125.1 mg/L) - preliminary evidence only
• Antibacterial effects shown by stem extracts against various pathogens (MIC: 60-100 mg/L) - in vitro studies only
• Antioxidant properties via DPPH and ABTS free radical scavenging attributed to phenylethanoid glycosides and flavonoids - laboratory evidence only
• Skin anti-aging potential through flower extract compounds like crocin and quercetin - limited to in vitro testing
• Tyrosinase inhibition by leaf extracts (IC50: 38.17 mg/L) suggesting skin-lightening properties - preliminary cell-based evidence

How It Works

Flavonoids in Buddleja davidii, particularly luteolin and apigenin, suppress the NF-κB signaling pathway and inhibit cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and downstream inflammatory mediators. Iridoid glycosides such as aucubin contribute to antioxidant activity by donating hydrogen atoms to neutralize DPPH and ABTS radicals, reducing oxidative stress at the cellular level. Stem-derived phenolic compounds disrupt bacterial cell membrane integrity against pathogens including Staphylococcus aureus and Escherichia coli, with minimum inhibitory concentrations (MIC) ranging from 60 to 100 mg/L in vitro.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses have been conducted on Buddleja davidii. Current evidence is limited to in vitro assays and preclinical studies examining antioxidant, anti-inflammatory, antibacterial, and antityrosinase activities at concentrations ranging from 28.6-200 mg/L.

Clinical Summary

Current evidence for Buddleja davidii is restricted to in vitro cell-culture and laboratory assays; no peer-reviewed human clinical trials have been published as of 2024. Flower extract demonstrated anti-inflammatory activity with IC50 values of 28.6–125.1 mg/L in cell-based models, while stem extracts showed antibacterial effects at MIC values of 60–100 mg/L against selected gram-positive and gram-negative bacteria. Antioxidant capacity has been quantified via DPPH and ABTS radical scavenging assays, though these results do not translate directly to confirmed human bioavailability or efficacy. The overall evidence base is preliminary, and controlled human trials are necessary before any therapeutic claims can be substantiated.

Nutritional Profile

Buddleja davidii is not a food ingredient and lacks conventional nutritional profiling (macronutrients, vitamins, minerals) in the literature. Bioactive compounds are the primary characterized constituents: Phenylethanoid glycosides are the dominant class, including acteoside (verbascoside) at approximately 0.5-2.1% dry weight in leaf/flower tissue, and echinacoside at lower concentrations (~0.1-0.5% dry weight). Flavonoids include luteolin, apigenin, linarin (acacetin-7-rutinoside), and buddleoside (luteolin-7-glucuronide), collectively estimated at 0.8-3.0% dry weight in flowers. Iridoid glycosides such as aucubin and catalpol are present in leaf material at trace to moderate levels (~0.05-0.3% dry weight). Caffeic acid derivatives and hydroxycinnamic acid esters contribute to total phenolic content, measured at approximately 15-45 mg GAE/g dry weight in flower extracts. Saponins and diterpenoids have been detected in stem bark. Essential oil fractions from flowers contain minor quantities of linalool, geraniol, and lilac aldehydes. Fiber, protein, and fat content are not meaningfully characterized as this plant is not consumed as food. Bioavailability of phenylethanoid glycosides is considered moderate based on related compounds in other species, with gut microbiota potentially hydrolyzing glycosidic bonds to release aglycones; no specific human bioavailability studies for B. davidii exist.

Preparation & Dosage

No clinically studied dosage ranges exist for human use. In vitro studies used extract concentrations up to 200 mg/L, which showed biological activity without cytotoxicity in human skin fibroblast cells. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, Luteolin, Green Tea Extract, Resveratrol, Vitamin C

Safety & Interactions

No formal human safety or toxicology studies have been conducted on Buddleja davidii extracts, making its safety profile in supplements largely unknown. The plant is classified as an invasive species in many regions and is not approved by the FDA or EFSA as a dietary supplement ingredient, raising regulatory concerns. Theoretical interactions with anti-inflammatory drugs (NSAIDs, corticosteroids) and anticoagulants are possible given its COX-inhibiting flavonoid content, though no interaction data exist in humans. Buddleja davidii should be avoided during pregnancy and breastfeeding due to a complete absence of safety data in these populations.